newsfilter
← Latest News
GlobeNewswire·

Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint topline data readout in Q1 2023 – – Sarepta extends O